Back to results
US 9,174,988 B2Granted
Small molecule inhibitors of hepatitis C virus
AssigneesTrustees of Boston University, The Scripps Research Institute
InventorsJohn K. Snyder, Wanguo Wei, Feng Ni, Arthur Donny Strosberg, Smitha Kota, Virginia Ngocthanh Takahashi
Life of this patent
Estimating the term…
Abstract
The invention provides derivatives and analogs of triazatetracyclo[7.7.0.01,13.02,7]-hexadeca-2,4,6,10,12-pentaenes, 5,7,11-triazatetracyclo[8.7.0.01,6.012,17]-heptadeca-6,8,12,14,16-pentaenes, pharmaceutical compositions comprising these compounds and methods for treatment of hepatitis C viral infections using these compounds.
Claims9
A compound having the structure shown in formula (I):
- wherein:
- X is CR13 or N;
- Y is O or S;
- R11 is H, C(O)R17, CO2R17, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted, or R11 is a linker that links two compounds of formula (I) together;
- R12 and R13 are independently for each occurrence H, halogen, N(R17)2, NO2, OR17, CF3, CN, C(O)R17, CO2R17, SO3R17, SR17, S(O)R17, S(O)2R17, CH(CO2R17)2, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl or heterocyclyl, each of which can be optionally substituted;
- R14 is C(O)R17, CO2R17, C(O)N(R17)2, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted;
- R15 is H, halogen, CF3, CN, —(CH2)tOR17 (t is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10), C(O)R17, CO2R17, OR17, SR17, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted;
- R16 is independently for each occurrence halogen, N(R17)2, NO2, OR17, CF3, CN, C(O)R17, CO2R17, SO3R17, SR17, S(O)R17, S(O)2R17, CH(CO2R17)2, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl or heterocyclyl, each of which can be optionally substituted;
- R17 is independently for each occurrence H, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, or heterocyclyl, each of which can be optionally substituted
- m is 1, 2, or 3;
- n is 0, 1, 2, 3, or 4;
- and
- stereoisomers and pharmaceutically acceptable salts thereof.
10 more elements
A pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier
- wherein formula I comprises
- wherein:
- X is CR13 or N;
- Y is O or S;
- R11 is H, C(O)R17, CO2R17, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted, or R11 is a linker that links two compounds of formula (I) together;
- R12 and R13 are independently for each occurrence H, halogen, N(R17)2, NO2, OR17, CF3, CN, C(O)R17, CO2R17, SO3R17, SR17, S(O)R17, S(O)2R17, CH(CO2R17)2, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl or heterocyclyl, each of which can be optionally substituted;
- R14 is C(O)R17, CO2R17, C(O)N(R17)2, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted;
- R15 is H, halogen, CF3, CN, —(CH2)tOR17 (t is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10), C(O)R17, CO2R17, OR17, SR17, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted;
- R16 is independently for each occurrence halogen, N(R17)2, NO2, OR17, CF3, CN, C(O)R17, CO2R17, SO3R17, SR17, S(O)R17, S(O)2R17, CH(CO2R17)2,
- alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl or heterocyclyl, each of which can be optionally substituted;
- R17 is independently for each occurrence H, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, or heterocyclyl, each of which can be optionally substituted
- m is 1, 2, or 3;
- n is 0, 1, 2, 3, or 4;
- and
- stereoisomers and pharmaceutically acceptable salts thereof.
12 more elements
A method of treating a disease or disorder caused by a Hepatitis C viral infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I),
- wherein formula I comprises
- wherein:
- X is CR13 or N;
- Y is O or S;
- R11 is H, C(O)R17, CO2R17, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted, or R11 is a linker that links two compounds of formula (I) together;
- R12 and R13 are independently for each occurrence H, halogen, N(R17)2, NO2, OR17, CF3, CN, C(O)R17, CO2R17, SO3R17, SR17, S(O)R17, S(O)2R17, CH(CO2R17)2, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl or heterocyclyl, each of which can be optionally substituted;
- R14 is C(O)R17, CO2R17, C(O)N(R17)2, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted;
- R15 is H, halogen, CF3, CN, —(CH2)tOR17 (t is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10), C(O)R17, CO2R17, OR17, SR17, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted;
- R16 is independently for each occurrence halogen, N(R17)2, NO2, OR17, CF3, CN, C(O)R17, CO2R17, SO3R17, SR17, S(O)R17, S(O)2R17, CH(CO2R17)2,
- alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl or heterocyclyl, each of which can be optionally substituted;
- R17 is independently for each occurrence H, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, or heterocyclyl, each of which can be optionally substituted
- m is 1, 2, or 3;
- n is 0, 1, 2, 3, or 4;
- and
- stereoisomers and pharmaceutically acceptable salts thereof.
12 more elements
Dependencies are inferred from the claim text.